HCPCS code J9026: Tarlatamab injection, per 1 mg2026 Medicare rate & RVUs in Missouri
Tarlatamab-dlle is an intravenous antineoplastic drug reported for each milligram administered to an eligible patient with small cell lung cancer.
CMS doesn’t publish an office rate for J9026 in Missouri.
Medicare allowed amount for participating (non-QP) physicians, before deductible, coinsurance and claim adjustments. Not a patient’s bill or a hospital charge.
Your location
On this page 9 sections
What J9026 covers
Tarlatamab-dlle (Imdelltra) is an intravenous immunotherapy used for adults with extensive-stage small cell lung cancer that has progressed during or after platinum-based chemotherapy. It engages T cells and cancer cells through DLL3, prompting an immune response against the tumor. Oncology clinicians administer it by infusion, typically in a hospital outpatient department or infusion center, with step-up dosing at treatment initiation.
J9026 represents 1 mg of tarlatamab-dlle, so the HCPCS unit count corresponds to the number of milligrams administered. CMS excludes the code from the physician fee schedule under status E. When Medicare covers the drug, payment is through another method; the HCPCS pricing method identifies it as a Part B drug generally paid using CMS quarterly Average Sales Price drug pricing files. Coverage is left to the Medicare contractor’s judgment.
This summary was written with AI assistance from CMS physician fee schedule data and checked against the CMS billing rules shown here. Rates on this page come directly from CMS files.
Where J9026 pays more and less in Missouri
The same RVUs, adjusted for each area’s costs. Open a locality for its calculation, history and nearby areas.
| Payment locality | Office | Facility |
|---|---|---|
| Metropolitan Kansas City, MO | Unavailable | Unavailable |
| Metropolitan St. Louis, MO | Unavailable | Unavailable |
| Rest of Missouri | Unavailable | Unavailable |
How the J9026 rate is calculated
Each of J9026’s three RVUs is multiplied by a geographic index (GPCI) for the payment locality, added up, and multiplied by the conversion factor. Drag the indexes or enter a ZIP to see what moves the rate.
How the rate is built · J9026
RVUs × geographic indexes × conversion factor
Work0.00
0.00 RVUs× 1.000 GPCI
Practice expense0.00
0.00 RVUs× 1.000 GPCI
Malpractice0.00
0.00 RVUs× 1.000 GPCI
Adjusted RVUs
0.0000
Conversion factor
$33.4009
Medicare rate
$0.00
Every GPCI starts at 1.000, the national rate. Enter a ZIP or drag a slider.
Payment rules and modifiers for J9026
J9026 has no global surgery period, no multiple-procedure, bilateral or assistant-at-surgery adjustment, and no professional/technical split. What changes the payment is where the service happens: the place of service on the claim decides whether Medicare pays the office or the facility rate.
Place of service · J9026
Which rate does Medicare pay?
The POS code on the claim line (CMS-1500 box 24B).
POS 11 · non-facility rate · national
—
J9026 isn’t priced in this setting.
J9026 compared with similar codes
Compare codes · National
4 codes, side by side
How to choose
- J9039BlinatumomabPer 1 mcg
- J9039 identifies blinatumomab, not tarlatamab-dlle; the drugs have different indications and HCPCS codes.
- J9022Atezolizumab injectionPer 10 mg
- J9022 identifies atezolizumab per 10 mg. J9026 identifies tarlatamab-dlle per 1 mg; select the code for the drug actually administered.
- J9023Avelumab injectionPer 10 mg
- J9023 identifies avelumab per 10 mg, a different antineoplastic drug. J9026 is specific to tarlatamab-dlle and uses a 1 mg unit.
J9026 billing questions
How does J9026 differ from J9039 for blinatumomab?
J9026 is for tarlatamab-dlle, used for small cell lung cancer. J9039 is for blinatumomab, a different drug used for certain acute lymphoblastic leukemia treatment.
How many units should be reported?
Report one unit for each milligram of tarlatamab-dlle administered. For example, 10 mg corresponds to 10 units.
What documentation supports the units?
The medication administration record should identify the administered tarlatamab-dlle dose in milligrams so the reported units can be calculated.
What administration code may accompany J9026?
CPT 96413 may be reported for the initial intravenous antineoplastic infusion service when its requirements are met. The drug code represents the medication, not the infusion service.
How does Medicare treat this code?
CMS assigns physician fee schedule status E, meaning the code is excluded from that schedule. When covered, it is treated as a Part B drug generally priced through CMS quarterly ASP files, and coverage is left to the Medicare contractor’s judgment.
Where these rates come from
FeeBase calculates base physician payments from CMS work, practice-expense and malpractice RVUs, adjusted by each locality’s geographic indexes and the conversion factor. Services without a published rate are labeled, never given a made-up amount. Amounts are Medicare allowed amounts before claim adjustments: not a patient’s bill or a commercial rate.
CMS RVU26D · effective Oct 1, 2026 through the day before Jan 1, 2027
Fee sheets · Coming soon
Put J9026 and the rest of your codes on one sheet
Your codes at your locality, with payer contracts beside Medicare.
Join the waitlist